Skip to main content
. 2022 May 26;18(3):e081221198647. doi: 10.2174/1573403X17666211208100151

Fig. (5).

Fig. (5)

Risk difference between the groups with subcutaneous implantable cardioverter defibrillators and implantable cardioverter defibrillators-transvenous for infection. (A higher resolution / colour version of this figure is available in the electronic copy of the article).